Drug Profile
Research programme: small molecule inflammatory disease therapeutics - AstraZeneca/Clinical Data
Alternative Names: AVN-1222Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Avalon Pharmaceuticals; MedImmune
- Developer AstraZeneca; Clinical Data
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 26 Apr 2012 Discontinued for Inflammation in USA (unspecified route)
- 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
- 21 Aug 2009 Research is ongoing in USA